12:22:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-11-20 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-28 Kvartalsrapport 2024-Q1
2024-05-15 X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-15 X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2020-08-20 08:00:00

(Stockholm, 20 August 2020) Inhalation Sciences AB (ISAB) is repositioning its Contract Research business and launching it under a new brand name - Inhalation Research Services (IRS). IRS offers a comprehensive service portfolio that delivers precise and predictive early-stage respiratory research data. IRS has seen a steady increase in demand from its biopharma customers and has grown considerably during the Covid-19 pandemic.

ISAB is organizing its operations into three business areas: The first is the sales of its PreciseInhale[® ]system and modules, the second is IRS, providing contract research services, and the third is publications and research partnerships with universities and academic institutions. All three are highly complementary and increased cross-sales between the three are expected. In addition, customers will benefit from a more comprehensive service offering, a higher degree of adaptable solutions and transparent pricing. The three business areas will also support ISAB to better utilize its own resources, monitor financial performance and measure margin improvements across the business.

IRS' FIVE CORE SERVICES will include; aerosol characterization, DissolvIt[® ]in vitro dissolution testing, IPL (isolated perfused lung), intratracheal testing and nose-only testing. IRS is attracting new customers at a time of growing need for more precise and predictive respiratory therapies.

CEO Manoush Masarrat, "ISAB has always been about the power of precision, and the precise, predictive data IRS delivers enables drug developers to eliminate risk and move beyond a `test and try' approach. They can plot a clear roadmap of which substances to invest in. Ultimately, it's about predicting exactly how your substance will behave throughout the lung, early on. That's what IRS data deliver."

In June 2020, the company's new chair, Daniel Spasic, joined ISAB. Spasic is a recognized leader in Contract Research and founded TFS International, a global clinical Research Organization that among several therapeutic areas also specialized in respiratory diseases. "With the data provided by IRS, inhaled drug developers can early on start designing clinical study protocols that are geared towards more predictive clinical outcomes and benefits for patients" Spasic, says.

CEO Manoush Masarrat: "IRS builds long-term customer relationships and demonstrates our capabilities and technology. During the current Coronavirus pandemic, revenues from IRS have remained robust. We're intensely proud of IRS, as we believe it will help the respiratory research community to benefit from the services and data we can provide".